These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32095513)

  • 1. Safe and Successful Treatment of Acute Cellular Rejection of an Intestine and Abdominal Wall Transplant With Vedolizumab.
    Trentadue G; Kats-Ugurlu G; Blokzijl T; Diercks GF; Haveman JW; Faber KN; Dijkstra G
    Transplant Direct; 2020 Feb; 6(2):e527. PubMed ID: 32095513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute cellular rejection in small-bowel transplantation impairs NCR
    Pucci Molineris M; González Polo V; Rumbo C; Fuxman C; Lowestein C; Nachman F; Rumbo M; Gondolesi G; Meier D
    Transpl Immunol; 2020 Jun; 60():101288. PubMed ID: 32209429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
    Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
    Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abdominal Wall Transplantation: Skin as a Sentinel Marker for Rejection.
    Gerlach UA; Vrakas G; Sawitzki B; Macedo R; Reddy S; Friend PJ; Giele H; Vaidya A
    Am J Transplant; 2016 Jun; 16(6):1892-900. PubMed ID: 26713513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
    Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
    Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
    Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe acute cellular rejection after intestinal transplantation is associated with poor patient and graft survival.
    Huard G; Schiano TD; Moon J; Iyer K
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28295657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential histologic changes in the healing process in small bowel allografts treated for acute cellular rejection.
    Liu L; Fischer RT; Xu L; Talmon GA
    Transplant Proc; 2013 Mar; 45(2):643-8. PubMed ID: 23267814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases.
    Luzentales-Simpson M; Pang YCF; Zhang A; Sousa JA; Sly LM
    Front Cell Dev Biol; 2021; 9():612830. PubMed ID: 33614645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
    J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes of Intestinal and Multivisceral Transplantation at a Single Center in Argentina.
    Ramisch D; Rumbo C; Echevarria C; Moulin L; Niveyro S; Orce G; Crivelli A; Martinez MI; Chavez L; Paez MA; Trentadue J; Klein F; Fernández A; Solar H; Gondolesi GE
    Transplant Proc; 2016 Mar; 48(2):457-62. PubMed ID: 27109978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
    Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative incidence of rejection occurring in small intestinal and colonic mucosal biopsies of patients undergoing intestinal transplantation.
    Huard G; Schiano T; Fiel MI; Ward SC; Moon J; Iyer K
    Histopathology; 2016 Oct; 69(4):600-6. PubMed ID: 27061581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting PGGT1B Disrupts Function of RHOA, Resulting in T-cell Expression of Integrin α4β7 and Development of Colitis in Mice.
    López-Posadas R; Fastancz P; Martínez-Sánchez LDC; Panteleev-Ivlev J; Thonn V; Kisseleva T; Becker LS; Schulz-Kuhnt A; Zundler S; Wirtz S; Atreya R; Carlé B; Friedrich O; Schürmann S; Waldner MJ; Neufert C; Brakebusch CH; Bergö MO; Neurath MF; Atreya I
    Gastroenterology; 2019 Nov; 157(5):1293-1309. PubMed ID: 31302143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.
    Ungar B; Malickova K; Hanžel J; Abu Arisha M; Paul S; Rocha C; Ben Shatach Z; Abitbol CM; Haj Natour O; Selinger L; Yavzori M; Fudim E; Picard O; Shoval I; Eliakim R; Kopylov U; Magro F; Roblin X; Chowers Y; Drobne D; Lukas M; Ben Horin S
    J Crohns Colitis; 2021 Oct; 15(10):1707-1719. PubMed ID: 33837762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of graft rejection in small bowel transplanted pigs after immunosuppression withdrawal.
    Viganó J; Abbiati F; Alessiani M; Bonfichi M; Zonta S; Bardone M; Zitelli E; Cobianchi L; Doni M; Lovisetto F; Dominioni T; De Martino M; Lusona B; Arbustini E; Dionigi P
    Transplant Proc; 2006; 38(6):1818-20. PubMed ID: 16908291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
    Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
    J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.